Please assess the completion status of the following clinical trial:

Trial Title: Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Histologically proven, invasive primary squamous, basaloid, or cloacogenic carcinoma of the anal canal, stage T1-4, N0-3~* No previous therapy for anal cancer.~* Age greater than or equal to 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2~* Adequate bone marrow, renal, and hepatic function defined as~  * Absolute neutrophil count greater than or equal to 1,000 cells/mm(3)~ * Platelet count greater than or equal to 100,000/mm(3)~ * Hemoglobin greater than or equal to 8mg/dL~ * Creatinine clearance \> 60 mL/min using Cockcroft-Gault formula~ * Bilirubin less than or equal to 1.5 times upper limit of normal (ULN) unless, during screening, the patient is receiving protease inhibitor therapy (i.e. indinavir, ritonavir, nelfinavir, and atazanavir) known to be associated with increased bilirubin: in this case total bilirubin less than or equal to 7.5 mg/dl and the direct fraction is less than or equal to 0.7 mg/dl.~ * White blood cell (WBC) greater than or equal to 3,000/microL~ * Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than or equal to 3 times the upper limit of normal~ * International normalized ratio (INR) less than or equal to 1.5~* Patients of childbearing potential must be willing to use a medically effective means of birth control for the duration of treatment and six weeks after treatment.~* Patients must be willing and able to provide informed consent~EXCLUSION CRITERIA:~* Contraindications to radiotherapy such as a history of prior radiotherapy to the pelvis or a history of inflammatory bowel disease~* Prior malignancy except:~  * non-melanoma skin cancer~ * controlled Kaposi's Sarcoma (no chemotherapy for KS for 3 months, and no expected need for chemotherapy for the 12-month period of the study)~ * other malignancies with disease free period of at least 3 years~* Presence of metastatic disease (M1)~* Co-morbidity that in the estimation of the principal investigator would make the patient unable to tolerate treatment~* Pregnant or lactating females~* Human immunodeficiency virus (HIV) positive patients with cluster of differentiation 4 (CD4) \< 100 cells/mL AND ECOG performance status (PS) greater than 2.~* Dermatitis in the anticipated radiation treatment portal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1/Chemo + Radiation (Type: EXPERIMENTAL): Chemo + Radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).